Pro Research: Wall Street eyes Cisco amid market shifts
Post Content
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
UiPath stock jumps 14% after ‘solid’ results
Post Content
IPC gets green light for stock buyback program
Post Content